Drug intelligence / Profile preview

B7-H3 targeting Affibody molecules

Development stage
Preclinical
Lead developer
Affibody
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous
01

Overview

B7-H3 targeting Affibody molecules are a class of small, engineered scaffold proteins designed to selectively bind to CD276 (B7-H3), an immune checkpoint protein overexpressed in various solid tumors, including neuroblastoma, ovarian cancer, and colorectal cancer. Developed by Affibody AB in collaboration with Uppsala University, these molecules are based on a three-helix bundle domain derived from staphylococcal protein A. Due to their small size (~6-7 kDa), they offer rapid tissue penetration and blood clearance, making them highly suitable for both precision diagnostic imaging (when labeled with radionuclides like Gallium-68 or Technetium-99m) and targeted radionuclide therapy (when fused with an albumin-binding domain for half-life extension and labeled with Lutetium-177). Preclinical studies have demonstrated high specificity, affinity, and tumor-targeting properties in various cancer models.

Other names
anti-B7-H3 affibody moleculesanti-B-7-H3 affibody moleculesanti-B 7-H3 affibody moleculesB7-H3 affibodiesB-7-H3 affibodiesB 7-H3 affibodiesB7-H3-targeting affibody moleculesB-7-H3-targeting affibody moleculesB 7-H3-targeting affibody molecules
02

Identity

Drug type
Non-Antibody Therapeutic Proteins
Modality
Recombinant Proteins and EnzymesPeptidesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Targets

Route
Intravenous
04

Development

IndicationHighest phaseStatus
colorectal cancer (CRC) and precursor lesionsPreclinicalActive
neuroblastomaPreclinicalActive
neuroblastoma (MYCN-amplified / non-amplified)PreclinicalActive
ovarian cancer and premalignant lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
83
Drugs in the lead indication
1,201

Lead indication: colorectal cancer (CRC) and precursor lesions

Most advanced in the lead indication

  1. afliberceptApproved
  2. bevacizumabApproved
  3. capecitabineApproved
  4. folinic acidApproved
  5. fruquintinibApproved

Beyond the preview

Go deeper on B7-H3 targeting Affibody molecules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on B7-H3 targeting Affibody molecules.

Work on B7-H3 targeting Affibody molecules? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call